Hinge Health 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Q3 2026 revenue was $235 million, up 52% from $154 million in Q3 of last year, while LTM calculated billings were $960 million, up 54% year over year.
- Gross margin was 88%, up 480 basis points from 83% in Q3 of last year; income from operations was $77 million, a 33% operating margin, and free cash flow was $120 million, excluding $7 million of one-time acquisition-related payments, with a 51% free cash flow margin.
- The company ended Q3 with $358 million in cash and investments, purchased 296,000 shares for $26 million through its share repurchase program, and reported a weighted average diluted share count of 86.5 million shares and diluted net income per share of 71 cents.
- Hinge Health had 3,270 contracted clients at the end of Q3, up 28% year over year, added three new Fortune 15 clients, and expanded to cover the full population of another.
- More than 10 million lives across over 800 clients had access to multiple Hinge Health products, and the company reported approximately 9 million lives across over 800 clients had access to migraine care.
- Since announcing the cylinder acquisition, the GI client base grew by around 40%; Hinge Select had approximately 5,500 provider locations as of Q3, mostly PT and imaging centers.
- Initial surveyed migraine members reported a 23% reduction in monthly migraine days, attacks shorter by roughly 5 hours or a 28% reduction in duration, and reduced monthly prescription use days; about two-thirds improved their HIT-6 score and just over half achieved a clinically meaningful change.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, everyone. Thank you for joining us, and welcome to the Hinge Health Third Quarter 2026 Earnings Call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please raise your hand. If you have dialed into today's call, please press star 9 to raise your hand and star 6 to unmute. I will now hand the conference over to Bianca Buck, Head of Investor Relations.
Bianca, please go ahead. Good afternoon, and welcome to Hinge Health's Third Quarter 2026 Earnings Call.
I'm Bianca Buck, Head of Investor Relations. With me on the call are Daniel Perez, our co-founder and CEO, Jim Pursley, our President, Aaryn Pure, our Chief Commercial Officer, and James Budge, our CFO. I want to thank everyone for joining us. As a reminder, this conference call is being recorded. All relevant materials are available on the Investor Relations section of our website. Today's discussion will include forward-looking statements, which are subject to various risks, uncertainties, and assumptions. These statements reflect our current views and expectations regarding future events, including the expected performance of our business, future financial results, and growth strategies. While these statements represent our good faith judgment and beliefs, actual results may differ materially from those projected or implied. We undertake no obligation to update any forward-looking statements except as required by law.
For a detailed discussion of the risks, please refer to our SEC filings, including our annual report on Form 10-K for the year ended December 31, 2025, and our quarterly reports on Form 10-Q. We expect to file our next quarterly report on Form 10-Q in the next week. All income statement financial measures discussed today, other than revenue, are non-GAAP. These measures should be viewed in addition to and not as a substitute for our GAAP results. Reconciliations to the most comparable GAAP measures are included in the appendix to our earnings release. With that, I'll turn it over to Dan.
Thanks, Bianca. Q3 was another strong proof point that automated care delivery works for our members, our clients, our partners, and our financials. Here's what I'll cover today. First, a quick snapshot of our Q3 financial performance and the momentum we're carrying. Second, a product update, what's working in our core MSK business, some early data from our Migraine Care Program, and I want to spend a few moments on what our GI Care Program is going to look like, since I know that's been a common question. Third, I'll hand it to Jim and Aaron for the commercial update, and Jim has a personal note he'd like to share as well. Lastly, James will take us through the financials and updated guidance before we open it up for questions. Before I begin, apologies for my hoarse voice. I'm fighting a cold, but we've got great numbers to report.
Let's dive in. Q3 saw strong top-line performance and all-time highs on profitability. Revenue came in at $235 million, up 52% from $154 million in Q3 of last year. Last 12 months, calculated billings were strong as well, up 54% year-over-year to $960 million. Gross margin came in at 88%, up about 480 basis points from the same period last year. On the bottom line, operating income came in at $77 million, a 33% operating margin, up about 1,300 basis points year-over-year. Free cash flow, excluding one-time acquisition-related payments, was $120 million, representing a 51% free cash flow margin. As you can see, the momentum we saw in the first half of the year has continued, and that's a testament to the team, product, and business we've built. Let me now turn to product.
Let's start with our core MSK product, where we've spent over a decade automating care and continue to see progress. A good example is Movement Analysis, which uses our TrueMotion technology to give members a quantitative, objective way to track their progress, and it's being used by more and more of our members. It scores them across joint angles, symmetry, and endurance, and gives them Hinge Scores so they can actually see how they're improving over time, rather than just feeling they might be. The data shows it is resonating. Members who use Movement Analysis are doing more computer vision-based exercises overall. We believe that when people can see their progress in real numbers, they adhere better.
We also began rolling out a redesigned exercise experience this quarter, with new exercises that load faster, preview clips that show members what's coming, and a new control bar that puts them in charge of their session. These might sound like small things, but they're critical to ensuring a consumer-grade product experience, why we're the top-rated digital MSK app, and something people want to open rather than feel they have to. This technical foundation for our MSK product is also what lets us add care for new conditions like Migraine and GI efficiently. We've built an extensible platform, and we believe this unified approach is a meaningful advantage for us in the market. Speaking of our new programs, let me turn to our Migraine Care Program. We're still in early access with clients, but the data we're seeing is genuinely exciting.
Initial results of our surveyed members show a 23% reduction in monthly migraine days, and when migraines did occur, members reported they were shorter by roughly five hours, or a 28% reduction in the duration of the attack. We're also seeing a meaningful reduction in monthly prescription use days, which matters both for members and for the clients paying for their care. We're also tracking HIT-6 scores. That's a validated six-item measure used widely in migraine research that captures what migraine actually takes away from someone. That is, their ability to focus, work, stay present, and get through their day. About two-thirds of our members improved their HIT-6 score, and just over half crossed the threshold for a clinically meaningful change. That's a really strong early signal, and we're looking forward to sharing more as the program scales.
Thirdly, many of you have asked what our GI Care Program will eventually look like in the unified offering, so let me walk you through it. It's the same playbook we've run in MSK and Migraine. We start with the member intake, create a personalized care program, apply technology to automate care delivery, supplement the technology with access to clinicians and connected hardware when applicable, and hold it all to the same clinical rigor as our other programs. Fortunately, our acquisition of Cylinder and the incredible team that built it has given us a big head start. Nearly one in two people with GI conditions also have MSK pain, and 70% of people with Migraine also have a GI condition. These conditions are connected, and most people can't always tell how. With Hinge Health, we make it easy.
When a member opens the Hinge Health app, our AI-powered intake screener, the same engine that triages MSK and Migraine members today, routes them to the right care automatically. Back pain, pelvic floor conditions, Migraine, GI, or all of the above. Our GI Care Program itself will have two main parts. First, AI that turns raw signals into action, including personalized care plans. Our food analysis model can read what's going into the gut from a photo, a voice note, or a text. Robin, our AI Care Assistant, connects that input to symptoms in real time. With our AI-powered stool scan, a member could capture a photo, and our technology analyzes stool according to the Bristol Stool Scale, capturing form, consistency, and volume, giving us a structured longitudinal dataset that both our models and our clinicians can act on.
Those signals feed personalized care plans that evolve as our model learns what's driving someone's symptoms. Second, immediate access to a multidisciplinary care team from day one. No referral needed. That means a GI specialist who could prescribe and make in-person referrals when needed, a dietician focused on triggers and nutrition, and a gut-brain therapist delivering cognitive behavioral therapy, which is the evidence-based standard of care for IBS. Moreover, one of the top referrals for GI symptoms is pelvic floor therapy, and we're the only GI solution with that embedded in the same app, available the same day. We're really excited about where this is headed, and we think our integrated vision is differentiated. The full integrated program is targeted for the summer of 2027. We're selling the existing GI Care Program today, and we plan to upgrade those clients when the integrated version is ready.
We expect meaningful growth in revenue contribution to come in 2028, once we've had a full 2027 selling season with the integrated program. While I love where Migraine and GI are headed, I want to remind everyone that core MSK is still our largest revenue contributor by a wide margin, is growing robustly, and we expect it to remain that way for years to come. The opportunity in MSK remains massively under-penetrated, and everything we're doing in Migraine and GI is built on the foundation of what we've achieved in MSK. With that, I'll hand it over to Jim. Jim joined us in 2021 and has helped take us from a couple hundred clients to over 3,200, and to partnerships with 60-plus health plans, PBMs, and TPAs. That distribution model is the second wall of our moat, and much of it was built under Jim and Aaron's leadership.
Jim, over to you. Thank you, Dan.
I very much appreciate the kind words. Before I hand things over, I want to share something personal with everyone on the call. After a lot of reflection, I have made the decision to step back from my role as President at the end of the year. This is not a decision I came to lightly, but after a couple of decades of running hard, building two companies, taking them both public, and leading through some really demanding chapters, I am ready to spend more time with my family. That time is something I cannot get back, and I have decided it is the right moment to prioritize it. I want to be clear, I am not stepping back entirely. I will be joining the Hinge Health board because I believe in this company, and I want to continue helping us grow.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
17 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
